Crystalline forms of a ras inhibitor

HK40137430APending Publication Date: 2026-09-11REVOLUTION MEDICINES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125371
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-14
Filing Date
2026-06-26
Publication Date
2026-09-11

Smart Images

  • Figure 00000055_0000
    Figure 00000055_0000
  • Figure 00000056_0000
    Figure 00000056_0000
  • Figure 00000057_0000
    Figure 00000057_0000
Patent Text Reader

Abstract

The disclosure features crystalline forms of Ras inhibitors, pharmaceutical compositions thereof, and their uses in the treatment of cancers.
Need to check novelty before this filing date? Find Prior Art

Description

This disclosure is characterized by the crystalline forms of Ras inhibitors, their pharmaceutical compositions, and their use in the treatment of cancer. (Abstract)

Claims

Claims1. A crystalline solid form of Compound A:Compound A or a solvate thereof.

2. The crystalline solid form of claim 1 , wherein Compound A or the solvate thereof is selected from Form 1 , Form 2, Form 3, or Form 4.

3. The crystalline solid form of claim 1 or 2, wherein Compound A or the solvate thereof is Form 1 .

4. The crystalline form of claim 3, having at least one peak at diffraction angle 20 (°) of 4.4 ± 0.5, 4.6 ± 0.5, or 5.1 ± 0.5 as measured by X-ray diffractometry by irradiation with Cu Ka X-rays or calculated from X-ray diffractometry.

5. A mixture of crystalline Forms 1 and 2 of Compound A:Compound A or a solvate thereof, having at least one peak at diffraction angle 20 (°) of 4.4 ± 0.5, 4.6 ± 0.5, or 4.8 ± 0.5 as measured by X-ray diffractometry by irradiation with Cu Ka X-rays or calculated from X-ray diffractometry.

6. A pharmaceutical composition comprising the crystalline forms of Compound A of any one of claims 1 to 5, or a solvate thereof, and a pharmaceutically acceptable carrier or excipient.

7. A method of making crystalline Form 1 or a mixture of crystalline Forms 1 and 2 ofCompound A,Compound A or a solvate thereof, comprising dissolving Compound A in a suitable solvent, precipitating the crystalline form(s) of Compound A by the addition of a suitable antisolvent, isolating the crystalline form(s) of Compound A, and drying the crystalline form(s) of Compound A.

8. A method of making crystalline Form 1 or a mixture of crystalline Forms 1 and 2 of Compound A,Compound A or a solvate thereof, comprising dissolving Compound A in a suitable solvent, precipitating the crystalline form(s) of Compound A by the evaporation of the suitable solvent, isolating the crystalline form(s) of Compound A, and drying the crystalline form(s) of Compound A.

9. A method of making crystalline Form 1 or a mixture of crystalline Forms 1 and 2 of Compound A,Compound A or a solvate thereof, comprising dissolving Compound A in a suitable solvent, precipitating the crystalline form(s) of Compound A under ambient conditions, the isolating the crystalline form(s) of Compound A, and drying of the crystalline form(s) of Compound A.

10. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of crystalline Form 1 or a mixture of crystalline Forms 1 and 2 of Compound A of any one of claims 1 -5, or a solvate thereof, or a pharmaceutical composition of claim 6.

11. A method of treating a Ras protein-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of crystalline Form 1 of Compound A or a mixture of crystalline Forms 1 and 2 of Compound A of any one of claims 1 -5, or a solvate thereof, or a pharmaceutical composition of claim 6.

12. A method of inhibiting a Ras protein in a cell, the method comprising contacting the cell with an effective amount of crystalline Form 1 or a mixture of crystalline Forms 1 and 2 of Compound A of any one of claims 1 -5, or a solvate thereof, or a pharmaceutical composition of claim 6.

13. The method or use of any one of claims 10-12, wherein the method further comprises administering an additional anticancer therapy.

14. The method of claim 13, wherein the additional anticancer therapy is the following:or a pharmaceutically acceptable salt thereof.